Business
Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":" WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that three preclinical posters on EDP-305, Enanta’s lead Farnesoid X receptor (FXR) agonist, will be presented today at The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 8-12, 2019 in Boston.\n\n\nEDP-305 poster presentations\n\n\nMonday, November 11, 2019: 8:00 AM - 5:30 PM, Hynes Convention Center, Hall B\n\n\n\nAbstract #2137: DECREASES IN SERUM 7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE (C4) CORRELATE WELL WITH ANTI-FIBROTIC EFFICACY OF EDP-305 IN NONALCOHOLIC STEATOHEPATITIS (NASH) AND BILIARY FIBROSIS ANIMAL MODELS\nSession: NAFLD and NASH Therapeutics: Pharmacologic and Other\n\n\n\n\nAbstract #2202: A NOVEL NON-BILE ACID FXR AGONIST EDP-305 POTENTLY SUPPRESSES LIVER INJURY AND FIBROSIS WITHOUT WORSENING OF DUCTULAR REACTION\nSession: NAFLD and NASH: Basic\n\n\n\n\nAbstract #2252: A NOVEL NON-BILE ACID FXR AGONIST EDP-305 PREVENTS PROGRESSION TO CIRRHOSIS IN THIOACETAMIDE-INDUCED MODEL IN RATS\nSession: NAFLD and NASH: Basic\n\n\n\nTo learn more about the meeting, please visit https://www.aasld.org/event/liver-meeting\n\n\nAbout EDP-305, a Farnesoid X Receptor (FXR) Agonist\n\n\nEDP-305 is a potent Farnesoid X Receptor (FXR) agonist and Enanta’s lead product candidate being developed for the treatment of NASH and PBC. FXR is a nuclear receptor and a main regulator of bile acid levels in the liver and small intestine. It responds to bile acids by regulating gene transcription of key enzymes and transporters, many of which play important roles in lipid metabolism, insulin resistance, inflammation, and fibrosis. EDP-305 represents a class of FXR agonists that has been designed to take advantage of increased binding interactions with the receptor. This non-bile acid class contains steroid and non-steroid components and does not contain the carboxylic acid group normally present in other classes of FXR agonists and natural bile acids that can lead to the formation of taurine and glycine conjugates.\n\n\nAbout NAFLD, NASH, and FXR\n\n\nNon-alcoholic fatty liver disease (NAFLD) is the accumulation of excessive fat in the form of triglycerides ...